XRF Scientific (XRF) H1 2025 earnings summary

Executive summary

• Revenue for the half-year ended 31 December 2024 was $28.7m, up slightly from $28.6m year-over-year, achieving record results.

• Net profit attributable to equity holders rose to $5.0m from $4.5m year-over-year, up 12%.

• Acquisitions of Labfit and the remaining 50% of Orbis Mining expanded product offerings and market reach.

• Strong activity driven by global mining sector, with international sales growth in Asia, the Americas, and Europe.

• Recurring revenue increased from consumable sales and platinum labware recycling.

Financial highlights

• Gross profit increased to $13.5m from $12.4m year-over-year.

• Profit before income tax was $7.0m, up from $6.1m year-over-year.

• Basic and diluted EPS rose to 3.6 cents from 3.3 cents year-over-year.

• Operating cash inflow more than doubled to $4.4m from $2.2m year-over-year.

• Dividends paid during the half-year totaled $5.4m, up from $4.5m year-over-year.

Outlook and guidance

• International sales growth expected to continue, supported by expanded distribution and recurring revenue streams.

• Labfit acquisition expected to contribute positively in the second half as initial loss reverses with invoiced sales.

• Orbis Mining acquisition anticipated to enhance group profitability and revenue diversification.

• German office returned to profitability, with positive outlook for the second half.

• Integration of Labfit progressing, with relocation to main factory scheduled for March 2025 quarter.